

1
2
3
4 PLEXXIKON INC.,
5
6 Plaintiff,
7
8 v.
9
10 NOVARTIS PHARMACEUTICALS
11 CORPORATION,
12 Defendant.

Case No. 17-cv-04405-HSG

13
14
15
16
17
18
**ORDER DENYING DEFENDANT'S
MOTION FOR SUMMARY
JUDGMENT**

19 Re: Dkt. No. 177


20 Pending before the Court is Defendant Novartis Pharmaceuticals Corporation's motion for
21 partial summary judgment that certain claims of U.S. Patent Nos. 9,469,640 (the "'640 Patent")
22 and 9,844,539 (the "'539 Patent") (together, the "Asserted Patents") are invalid as anticipated
23 under 35 U.S.C. § 102.¹ The dispute, as briefed by the parties, centers on the priority date of the
24 Asserted Patents. For the reasons stated below, the Court finds that genuine disputes of fact
regarding that priority date remain and therefore **DENIES** the motion for summary judgment.

25 **I. BACKGROUND**

26 Plaintiff Plexxikon Inc. ("Plexxikon") brings this patent infringement action against
27 Novartis Pharmaceuticals Corporation ("Novartis") for infringement of the '640 and '539 Patents.
28 Plexxikon accuses Novartis' melanoma cancer drug Tafinlar, which treats melanoma by inhibiting
a protein called B-Raf kinase. The Asserted Patents cover a class of molecular compounds having
the following molecular structure:


29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845

United States District Court
Northern District of California



Dkt. No. 177-16 ('640 Patent) at claim 1; Dkt. No. 210-17 ('539 Patent) at claim 1.

As analyzed by Plexxikon’s expert, Dr. Michael Metzker, the claimed molecular structure has a “1,2,3-substituted” pattern of sulfonamide, fluorine, and a monocyclic heteroaryl. See Dkt. No. 399-2 (“Metzker Report”) ¶ 30. Specifically, as illustrated by Plexxikon below, the claimed structure has a phenyl ring (shown as a hexagon) having a sulfonamide (circled in red) at the “1” position, followed by a fluorine (circled in green) at the “2” position, and a linker L₁ (circled in blue) connecting a monocyclic heteroaryl at the “3” position. Dkt. No. 393-2 (“Metzker Depo.”) at 192:18-23; Metzker Report ¶ 28.²




Dr. Metzker refers to this combination as a “scaffold.” *Id.* In addition to the scaffold, the claimed molecular structure also includes a number of variables, marked as R¹, R², R³, R⁴, and m. Some of these variables, including R¹, R², and R³, are not part of the scaffold. *See* Dkt. No. 177-2 (“Baran Decl.”) ¶ 14. Instead, the variables may be one of a number of alternative elements. For instance, R¹ may be an optionally substituted lower alkyl or heteroaryl, while R³ may be an optionally substituted lower alkyl or aryl. ’640 Patent at claim 1; ’539 Patent at claim 1. R² is a

² Dkt. No. 167 (“Plexxikon MSJ”) at 5. Dr. Metzker does not provide the figure shown by Plexxikon, but confirmed a similar analysis in his deposition. See Metzker Depo. at 192:18-23; cf. Dkt. No. 397-1 (“Baran Depo.”) at 83:3-13. Novartis adopts Plexxikon’s scaffold characterization in its motion.

1 hydrogen or halogen. *Id.* The linker L₁ may also be eliminated for a direct bond. *Id.*

2 Plexxikon claims a priority date of March 2005.³ See Dkt. No. 179-6 at 8. Although the
 3 provisional application for the Asserted Patents was not filed until July 17, 2007, Plexxikon argues
 4 that the claimed inventions were conceived on March 14, 2005. Metzker Report ¶ 23. As support,
 5 Plexxikon cites an email with the subject line “new scaffold” sent by James Tsai, a co-inventor of
 6 the patents, on March 15, 2005, stating as follows:

7 **Hi**
 8 **To follow-up with our discussions on Chao's idea of novel scaffold discovery along 3204**
 9 **Chao's ideas**
 10 1. The Phe(2F)-N-SO₂-Z of 3204 series should be considered as a scaffold, making interactions
 with the DFG-activation loop region and move a few amino acids substantially.
 11 2. These interactions are novel, and we should consider modifications at X and abandon
 azaindole altogether.
 12 3. Chao's first suggestion at X is a Pyr, similar to gleevec
 13 4. The ketone linker, making hydrophilic interaction with water to stabilize the overall structure,
 does not need to stay
 14 5. I asked Yong to model this and other possible modifications at X



18
 19 Dkt. No. 212-4 (“March 2005 Email”).
 20
 21

22 Dr. Metzker opines that the March 2005 email discloses the claimed scaffold. Metzker
 23

24
 25
 26
 27 ³ Plexxikon also argues, in the alternative, that the patents are entitled to a priority date of
 February 2, 2007. However, the Court granted the motion to strike expert testimony supporting
 that priority date, which disposes of that priority theory. See Dkt. No. 416.
 28

1 Report ¶¶ 29-33. In particular, the email shows five compounds that have a phenyl ring with a
2 sulfonamide at the “1” position, a fluorine at the “2” position, and an “X” in the “3” position. *Id.* ¶
3 30. The “X” is a variable. *Id.* The email states that “Chao’s first suggestion at X is a Pyr,” which
4 the inventors interpreted as a pyridine—a monocyclic heteroaryl. *Id.* ¶¶ 32, 44, 46. In addition,
5 the email describes a variable “Z” attached to the sulfonamide, which the drawings show as certain
6 alkyl and phenyl groups. *Id.* ¶ 31; *see also* Dkt. No. 219 (“Ibrahim Decl.”) ¶ 5.

7 Jiazhong Zhang, another named inventor of the Asserted Patents, synthesized a compound
8 as “proof of concept” of the ideas in the March 2005 email, which Plexxikon designated P-0001,
9 between March 16 and March 18, 2005. Metzker Report ¶ 35. Plexxikon synthesized two other
10 compounds, designated P-0007 and P-0012, in December 2006 and January 2007, respectively.
11 *Id.* Dr. Metzker opines that each of these compounds falls within the scope of the claims, but does
12 not provide any details regarding their implementation. *Id.*

13 II. **LEGAL STANDARD**

14 A. **Summary Judgment**

15 A motion for summary judgment should be granted where there is no genuine issue of
16 material fact and the movant is entitled to judgment as a matter of law. Fed. R. Civ. P. 56;
17 *Anderson v. Liberty Lobby, Inc.*, 477 U.S. 242, 247–48 (1986). The purpose of summary
18 judgment “is to isolate and dispose of factually unsupported claims or defenses.” *Celotex v.*
19 *Catrett*, 477 U.S. 317, 323–24 (1986). The moving party has the initial burden of informing the
20 Court of the basis for the motion and identifying those portions of the pleadings, depositions,
21 answers to interrogatories, admissions, or affidavits which demonstrate the absence of a triable
22 issue of material fact. *Id.* at 323.

23 If the moving party meets its initial burden, the burden shifts to the non-moving party to
24 present facts showing a genuine issue of material fact for trial. Fed. R. Civ. P. 56; *Celotex*, 477
25 U.S. at 324. The Court must view the evidence in the light most favorable to the nonmovant,
26 drawing all reasonable inferences in its favor. *T.W. Elec. Serv., Inc. v. Pac. Elec. Contractors*
27 *Ass’n*, 809 F.2d 626, 630–31 (9th Cir. 1987). Summary judgment is not appropriate if the
28 nonmoving party presents evidence from which a reasonable jury could resolve the disputed issue

1 of material fact in the nonmovant's favor. *Anderson*, 477 U.S. at 248. Nonetheless, “[w]here the
2 record taken as a whole could not lead a rational trier of fact to find for the non-moving party,
3 there is no genuine issue for trial.” *Matsushita Elec. Indus. Co. v. Zenith Radio*, 475 U.S. 574, 587
4 (1986) (internal quotation mark omitted).

5 III. DISCUSSION

6 Novartis argues that certain compounds synthesized in 2007 anticipate some claims of the
7 Asserted Patents. Plexxikon does not directly dispute that these compounds fall within the scope
8 of the claims. Instead, Plexxikon argues that the compounds are not prior art for two reasons.
9 First, Plexxikon argues, citing Rule 131 case law, that the compounds were obvious variations of
10 Plexxikon's own inventions in the form of the P-0001, P-0007, and P-0012 compounds. Second,
11 Plexxikon claims entitlement to an earlier priority date based on conception of the species shown
12 in the March 2005 email. Novartis responds that Plexxikon's evidence is not sufficient to support
13 these arguments, and that even if it was, conception of a species cannot establish priority for a
14 claimed genus absent evidence of “generic applicability.”

15 As explained further below, the Court finds that Rule 131 law does not apply to the current
16 dispute. The Court therefore considers only (1) whether Plexxikon has produced enough evidence
17 to show prior conception of a claimed species, and (2) whether such evidence may suffice to
18 establish priority for the claims as a matter of law.

19 A. Legal Standard

20 1. Establishing Priority

21 Under 35 U.S.C. § 102(g), a patent is invalid if “before such person’s invention thereof,
22 the invention was made in this country by another inventor who had not abandoned, suppressed, or
23 concealed it.”⁴ “The invention date is the date of conception.” *Allergan, Inc. v. Apotex Inc.*, 754
24 F.3d 952, 967 (Fed. Cir. 2014). Conception is “the formation in the mind of the inventor, of a

25
26 ⁴ The America Invents Act (“AIA”) eliminated section 102(g) and applies to patents having an
27 effective filing date on or after March 16, 2013. See *Solvay S.A. v. Honeywell Int'l Inc.*, 742 F.3d
28 998, 1000 n.1 (Fed. Cir. 2014). Novartis disputes that Plexxikon is entitled to a priority date
before that time, but assumes that the pre-AIA statute applies for purposes of its motion.

1 definite and permanent idea of the complete and operative invention, as it is hereafter to be applied
2 in practice.” *Id.* at 967 (citation omitted). Conception is definite when the inventors have “a
3 specific, settled idea” and a “particular solution to the problem at hand.” *Dawson v. Dawson*, 710
4 F.3d 1347, 1352 (Fed. Cir. 2013) (quoting *Burroughs Wellcome Co. v. Barr Labs., Inc.*, 40 F.3d
5 1223, 1228 (Fed. Cir. 1994)). Conception is complete when “the idea is so clearly defined in the
6 inventor’s mind that only ordinary skill would be necessary to reduce the invention to practice,
7 without extensive research or experimentation.” *Id.* For chemical inventions, conception requires
8 both “(1) the idea of the structure of the chemical compound, and (2) possession of an operative
9 method of making it.” *Oka v. Youssefye*, 849 F.2d 581, 583 (Fed. Cir. 1998).

10 It is well-established that conception must include each claimed limitation. *See REG*
11 *Synthetic Fuels, LLC v. Neste Oil Oyj*, 841 F.3d 954, 962 (Fed. Cir. 2016) (“Conception must
12 include every feature or limitation of the claimed invention.”); *Cumberland Pharma. Inc. v. Mylan*
13 *Inst. LLC*, 846 F.3d 1213, 1218 (Fed. Cir. 2017) (“Conception is keyed to the *claimed* invention:
14 ‘A conception must encompass all limitations of the claimed invention.’” (emphasis in original)
15 (citation omitted)); *Taurus IP, LLC v. DaimlerChrysler Corp.*, 726 F.3d 1306, 1323 (Fed. Cir.
16 2013) (rejecting conception for failure to demonstrate the evidence “satisfie[d] all the limitations,
17 as necessary to demonstrate conception”). For inventions of chemical compounds, the compound
18 must be conceived “with all of [its] component substituents.” *Bd. of Edu. ex rel. Bd. of Tr. of Fla.*
19 *State Univ. v. Am. Bioscience, Inc.*, 333 F.3d 1330, 1340 (Fed. Cir. 2003).⁵

20 Where a patent claims a genus, conception of a species *may* constitute conception of a
21 genus. *Jolley*, 308 F.3d at 1322 & n.2; *Oka*, 849 F.2d at 584; *In re Taub*, 348 F.2d 556, 562
22 (C.C.P.A. 1965). The Federal Circuit has never expressly held that it does. *Jolley*, 308 F.3d at
23 1322 n.2.⁶ However, the Board of Patent Appeals and Interferences has so held, and the Federal

24 _____
25 ⁵ Plexxikon argues otherwise, Opp. at 12:12-12:16, but concedes this requirement in its proposed
26 jury instructions. *See* Dkt. No. 357 at 78:21-22. *In re Jolley* does not address the issue; it merely
27 discusses the particularity required to show conception of one limitation. 308 F.3d 1317, 1325
(Fed. Cir. 2002) (agreeing there was no conception where “there is no evidence in the record that
all of the elements of the count resided in the inventor’s mind”).

28 ⁶ In *Jolley*, the court found that conception of a species sufficed because the parties expressly
conceded the argument. 308 F.3d at 1322 n.2.

1 Circuit has repeatedly suggested as much. *Id.*; see *Oka*, 849 F.2d at 584 (citing the rule with
 2 approval but finding that patentee did not establish conception); *Taub*, 348 F.2d at 562 (noting in
 3 dicta that “one may establish priority for a generic claim on the basis of a showing that [the
 4 patentee] was prior as to a single species”). Moreover, the Federal Circuit has held that reduction
 5 to practice of a species suffices to show priority for a genus. See *Frazer v. Schlegel*, 498 F.3d
 6 1283, 1287, 1289 (Fed. Cir. 2007); see also *Miller v. Walker*, 214 U.S.P.Q. 845 (B.P.A.I. 1982)
 7 (citing reduction to practice cases in concluding that conception of a species suffices to establish
 8 priority for a genus).⁷

9 Assuming that conception of a species suffices, the species still must be described with
 10 particularity to show invention. See *Burroughs*, 40 F.3d at 1228 (noting that “[t]he conception
 11 analysis necessarily turns on the inventor’s ability to describe his invention with particularity”);
 12 see also *Amgen, Inc. v. Chugai Pharma. Co., Ltd.*, 927 F.2d 1200, 1206 (Fed. Cir. 1991)
 13 (requiring conception of a chemical compound to be so “definite” as to “distinguish it from other
 14 materials”). Where evidence of conception discloses compounds broader than the invention, the
 15 evidence must “fairly suggest to one of ordinary skill the subject matter of the [claim], without the
 16 need for extensive experimentation to ascertain whether the matter encompassed by the disclosure
 17 suggests that desirable features of compositions belonging to the [claim].” *Jolley*, 308 F.3d at
 18 1323; see also *Prutton v. Fuller*, 230 F.2d 459, 463 (C.C.P.A. 1956) (considering “the indication
 19 or lack of indication of a preference for the [claimed] composition” among broader disclosure).
 20 This is a “fact-intensive inquiry.” *Jolley*, 308 F.3d at 1323.

21 In *Jolley*, a party in an interference proceeding claimed a “two-component system”
 22 comprising (1) a refrigerant, and (2) certain esters.⁸ 308 F.3d at 1319. Another party attempted to

24 ⁷ Under the somewhat complex rules of pre-AIA priority, reduction to practice demonstrates
 25 invention (because it necessarily shows conception) unless the other party can establish an earlier
 26 conception combined with reasonable diligence in reducing to practice. See *E.I. du Point de
 Nemours & Co. v. Unifrax I LLC*, 921 F.3d 1060, 1075 (Fed. Cir. 2019).

27 ⁸ An interference proceeding was a pre-AIA administrative mechanism to “determin[e] which of
 28 competing applicants is the first inventor of the common subject matter.” *Capon v. Eshhar*, 418
 F.3d 1349, 1351 (Fed. Cir. 2005). A “count” in an interference proceeding is similar to a patent
 claim. See *Mycogen Plant Sci. v. Monsanto Co.*, 243 F.3d 1316, 1332 (Fed. Cir. 2001).

1 show conception using an email that disclosed each of these components, except that the esters
2 were broader than those claimed. *Id.* at 1321. Thus, some of the esters fell within the scope of the
3 count, while others did not. *Id.* at 1322. The Federal Circuit affirmed conception based on that
4 email because other evidence showed that the inventors held “particular interest” in esters falling
5 within the count. *Id.* at 1325-26. Specifically, the inventors’ company already manufactured
6 esters falling within the count and turned to them first when testing the invention. *Id.* at 1325.
7 Moreover, the inventors did not engage in extensive experimentation with esters outside the scope
8 of the count. *Id.* The court thus concluded that a “reasonable mind might accept as adequate [this]
9 evidence” of conception. *Id.* at 1326.

10 In *Bosies v. Benedict*, on the other hand, the Federal Circuit found that the party failed to
11 meet its burden to show conception. 27 F.3d 539, 544 (Fed. Cir. 1994). There, the claims recited
12 a chemical compound having an “A” group with a hydrocarbon chain of two to eight carbons. *Id.*
13 at 540. A party attempted to establish priority by introducing a laboratory notebook that showed
14 the same compound, but that had a variable “n” for the number of carbons. *Id.* at 541. The
15 Federal Circuit found that the notebook did not establish conception because there was insufficient
16 evidence that the inventors considered appropriate values for “n.” *Id.* at 542; *see also Prutton*, 230
17 F.2d at 464 (rejecting conception where the evidence contained “disclosures of a scope which
18 embraces the specific compositions recited by the claims” among others, but did not “fairly
19 suggest any preference for the claimed compositions”).

20 Because conception is a mental act, an inventor’s testimony alone is insufficient to prove
21 conception absent corroboration. *NFC Tech., LLC v. Matal*, 871 F.3d 1367, 1371 (Fed. Cir.
22 2017). “There is no particular formula that an inventor must follow in providing corroboration,”
23 which is evaluated under a flexible “rule of reason” that considers “all pertinent evidence.” *Singh*
24 v. *Brake*, 317 F.3d 1334, 1341 (Fed. Cir. 2003). Under that rule, corroborating evidence need not
25 support every limitation exactly as claimed. For instance, in *Unifrax*, the court found conception
26 sufficiently corroborated, even though no document showed conception of the claimed material
27 ranges (e.g., “a dry areal weight of 15 to 50 gsm”), because the documents showed broad testing
28 of elements within the claimed range. 921 F.3d at 1076-78. The court noted that “our case law

1 does not require that evidence have a source independent of the inventors on every aspect of
 2 conception and reduction to practice,” because such a rule would be “the antithesis of the rule of
 3 reason.” *Id.* at 1077 (citation omitted). *But see Jolley*, 308 F.3d at 1323 (“[A] preference for
 4 particular subject matter . . . must also be established on the basis of objective evidence.”).

5 A party challenging patent validity has the burden to prove by clear and convincing
 6 evidence that an invalidating reference is prior art. *Allergan*, 754 F.3d at 967. However, the
 7 burden of production may shift in the course of that determination. *See id.* Thus, where a party
 8 makes a *prima facie* case of invalidity, the burden of production shifts to the patentee to provide
 9 evidence and argument supporting an earlier priority date. *Tech. Licensing Corp. v. Videotek, Inc.*,
 10 545 F.3d 1316, 1327 (Fed. Cir. 2008). Once that showing is made, the burden shifts back to the
 11 party challenging validity to “convince the court that [the patentee] is not entitled to the benefit of
 12 the earlier [priority] date.” *Id.* at 1328. The ultimate burden of persuasion—and thus the “risk of
 13 decisional uncertainty”—never shifts from the party challenging validity. *Id.* at 1327.⁹

14 **2. Rule 131 Cases**

15 Notwithstanding the clear standard set out above, both parties attempt to import additional
 16 requirements from Rule 131 of the Patent and Trademark Office (“PTO”). *See Opp.* at 8:2-11:3;
 17 *Reply* at 9:16-10:10.¹⁰ Rule 131, codified in the federal register, states:

18 When any claim of an application or a patent under reexamination is
 19 rejected, the applicant or patent owner may submit an appropriate
 20 oath or declaration to establish invention of the subject matter of the
 21 rejected claim prior to the effective date of the reference or activity
 22 on which the rejection is based.

23 37 C.F.R. § 1.131(a). This rule has been described as a “swearing back” or “swearing behind”

24
 25 ⁹ Novartis argues that Plexxikon has the burden to prove an earlier priority date, but cites only
 26 administrative cases for that proposition. *See ATI Techs. ULC v. Iancu*, 920 F.3d 1362, 1370 (Fed.
 27 Cir. 2019); *In re Mangum Oil Tools Int'l, Ltd.*, 829 F.3d 1364, 1376 (Fed. Cir. 2016).

28
 29 ¹⁰ Plexxikon cites Rule 131 cases to argue that its compounds “antedate” the compounds at issue
 30 because its own inventions render the compounds obvious. *See In re Scheiber*, 587 F.2d 59, 61–
 31 62 (C.C.P.A. 1978); *In re Schaub*, 537 F.2d 509, 512 (C.C.P.A. 1976). Novartis cites Rule 131
 32 cases to argue that conception of a species does not suffice to establish priority of a genus unless
 33 the patentee “considered the invention to be a generic one” and provides a “reasonable basis” to
 34 infer generic applicability. *In re Walsh*, 424 F.2d 1105, 1107 (C.C.P.A. 1970); *In re Rainer*, 390
 35 F.2d 771, 774 (C.C.P.A. 1968); *In re DaFano*, 392 F.2d 280, 284 (C.C.P.A. 1968); *In re Clarke*,
 36 356 F.2d 987, 992 (C.C.P.A. 1966).

provision because it allows a patentee to antedate prior art by “swearing” in an affidavit that its invention occurred earlier. *Iancu*, 920 F.3d at 1369. In contrast to modern conception law, the predecessor court to the Federal Circuit required a Rule 131 affidavit to show priority “with respect to only so much of the claimed invention as the references disclose” or “only so much as to render the claimed invention obvious.” *See Scheiber*, 587 F.2d at 61-62 (citations omitted). The PTO continues to apply this standard, but the Federal Circuit apparently has not approved it and still requires Rule 131 affidavits to show conception of the “complete and operative invention.” *See In re Steed*, 802 F.3d 1311, 1320 (Fed. Cir. 2015).¹¹

Neither party establishes that Rule 131 cases apply to the current proceedings, and multiple factors suggest they should not. First, Rule 131 is an administrative rule that, on its face, applies only to reexaminations. Reexamination proceedings do not generally determine priority. *See Slip Track Sys., Inc. v. Metal Lite, Inc.*, 159 F.3d 1337, 1340 (Fed. Cir. 1998). Moreover, courts routinely reject any applicability of PTO proceeding decisions to district court litigation, and vice versa, given the different burdens and presumptions of validity. *See In re Baxter Int'l, Inc.*, 678 F.3d 1357, 1364 (Fed. Cir. 2012) (“[T]he PTO in reexamination proceedings and the court system in patent infringement actions ‘take different approaches in determining validity and on the same evidence could correctly come to different conclusions.’”) (quoting *Ethicon, Inc. v. Quigg*, 849 F.2d 1422, 1428 (Fed. Cir. 1998)); *In re Swanson*, 540 F.3d 1368, 1377 (Fed. Cir. 2008) (“PTO examination procedures have distinctly different standards, parties, purposes, and outcomes compared to civil litigation.”).

Second, the predecessor court to the Federal Circuit stated that “[t]he purpose of filing a 131 affidavit is not to demonstrate prior invention per se, but merely to antedate the effective date of the reference.” *In re Eickmeyer*, 602 F.2d 974, 978 (CCPA 1979). Under that standard, the court construed Rule 131 “liberally” and “in one respect contrary to its express terms” in order to assure

¹¹ In *Steed*, the court stated that “[w]hen the issue of priority concerns antedating of a reference, the applicant is required to demonstrate . . . that the applicant was in possession of the later claimed invention before the effective date of the reference.” 802 F.3d at 1316 (emphasis added). Nothing in *Steed* suggests the comparative approach urged by the parties here, which makes conception relative to the prior art. Nor do cases arising from district court litigation suggest that anything less than full conception suffices. *See Unifrax*, 921 F.3d at 1075-76 (discussing antedating a reference in litigation); *Taurus*, 726 F.3d at 1322-24 (same).

1 patentees their rights. *See In re Mulder*, 716 F.2d 1542, 1545-46 (Fed. Cir. 1983). However, it
 2 expressly rejected any similarity between this liberal construction and the substantive standards for
 3 conception and reduction to practice under 35 U.S.C. § 102(g). *See In re Moore*, 444 F.2d 572, 580
 4 (C.C.P.A. 1971) (characterizing any parallel as “one of convenience rather than of necessity”).¹²

5 Third, even if Rule 131 applied, it might not change the analysis. Each of the cases cited by
 6 the parties stems from the seminal decision in *In re Stempel*, 241 F.2d 755 (C.C.P.A. 1957), which
 7 held that a patent applicant may overcome a reference as to generic claims by showing priority to the
 8 species shown in that reference. The broad language of *Stempel* was later clarified in *In re Tanczyn*,
 9 347 F.2d 830 (C.C.P.A. 1965), which stated:

10 We never intended by the language used in *Stempel* to authorize the
 11 overcoming of references by affidavits showing that the applicant had
 12 invented, prior to the reference date, a part, some parts, or even a
 13 combination of parts, used to create an embodiment of his claimed
 14 invention, where the part or parts are not within the scope of the
 15 claims being sought, as the species of *Stempel* shown by the reference
 16 was within his generic claims.

17 *Id.* at 833; *see Isco Int'l, Inc. v. Conductus, Inc.*, 279 F. Supp. 2d 489, 495 n.3 (D. Del. 2003).

18 In other words, the Rule 131 cases still require a patentee to show conception of a species of
 19 the invention—not some compound outside the claims that merely renders the invention obvious.¹³
 20 This interpretation is confirmed by recent decisions that analyze the cases cited by the parties. *See*
 21 *Pernix Ireland Pain DAC v. Alvogen Malta Op. Ltd.*, No. 16-139-WCB, 2018 WL 2225113, at *16 (D.

22 ¹² *Moore* distinguished interference proceedings under 35 U.S.C. § 102(g)(1), not prior art
 23 determinations under 35 U.S.C. § 102(g)(2), but the statutory standard is the same. *Compare* 35
 24 U.S.C. § 102(g)(1) (“another inventor involved [in an interference] establishes . . . that before such
 25 person’s invention thereof the invention was made by such other inventor and not abandoned,
 26 suppressed, or concealed”), *with id.* § 102(g)(2) (“before such person’s invention thereof, the
 27 invention was made in this country by another inventor who had not abandoned, suppressed, or
 28 concealed it”).

29 ¹³ The Court recognizes contrary authority in *In re Spiller*, where the predecessor court of the
 30 Federal Circuit allowed a Rule 131 affidavit that did not show possession of one limitation. 500
 31 F.2d 1170, 1177 (C.C.P.A. 1974). *Spiller* has been described as “plainly inconsistent” with other
 32 holdings by that court. R. Carl Moy, 2 Moy’s Walker on Patents § 8.134 (4th ed. Dec. 2020); *see*
 33 *In re Goddard*, 2009 WL 2807704 (B.P.A.I. 2009). *Spiller* also appears to have been implicitly
 34 overruled by *Burroughs*, which rejected conception based on other inventions that render the
 35 claims obvious. *See* 40 F.3d at 1231-32.


1 Del. May 15, 2018) (interpreting the cited cases to require showing “that the inventors possessed
 2 knowledge of the species contained in both the reference and the patent”); *Abbott GMBH & Co., KG v.*
 3 *Centocor Ortho Biotech, Inc.*, 870 F. Supp. 2d 206, 245 (D. Mass. 2012) (same) (finding disputes of
 4 fact as to whether patentee invented a claimed species).

5 Under *Jolley* and the cases analyzed above, conception of a species may suffice to establish
 6 conception for a genus. Rule 131 imposes the same standard, but potentially adds requirements for
 7 generic applicability or prior art obviousness. *Pernix*, 2018 WL 2225113, at *14. The Court interprets
 8 these additional requirements as persuasive authority, but finds them not binding for the reasons stated
 9 above. Accordingly, Rule 131 case law does not directly apply to this litigation.¹⁴

10 **B. Analysis**

11 **1. Conception of a Species**

12 Turning to the merits, the Court first considers whether Plexxikon submits sufficient
 13 evidence that its inventors conceived a species of the claims before 2007. Plexxikon relies
 14 primarily on the March 2005 email to argue that they did. The Court has created the following
 15 graphic to illustrate the differences between the email figures and the claimed compounds. See
 16 Ibrahim Decl. ¶¶ 7-9 (mapping email to claim limitations).



17

18

19

20

21

22

23

24

25

26

27

28

¹⁴ For this reason, the Court does not consider whether Plexxikon’s synthesis of P-0001, P-0007, and P-0012 compounds render the compounds at issue obvious. There is insufficient evidence that the former compounds fall within the scope of the claims. To the extent that they do, Plexxikon may presumably establish priority based on reduction to practice, regardless of the obviousness of other compounds. See *Unifrax*, 921 F.3d at 1075.

1 As shown above, Novartis does not dispute that the email shows a phenyl ring attached to a
2 sulfonamide at the “1” position and a fluorine in the “2” position.¹⁵ *See* MSJ at 7:2-28; *see also*
3 Dkt. No. 393-39 (“Baran Reply Decl.”) ¶ 2. Novartis also does not dispute that the drawings show
4 a hydrogen as R⁴. *Id.* Novartis argues, however, that the email does not show conception of the
5 monocyclic heteroaryl group, which is shown generically as “X,” or the remaining variables. The
6 issue thus centers on whether the evidence “fairly suggests” appropriate values for those elements.
7 *Jolley*, 308 F.3d at 1323.

8 With respect to “X,” the inventors testified that they conceived “X” to include “any moiety
9 that could interact with the hinge region of the kinase.” Metzker Report ¶ 32 (citing testimony).
10 Plexxikon proffers declarations attesting that this includes all groups corresponding to L₁-Ar-
11 (R¹)_m. Ibrahim Decl. ¶ 7; Dkt. No. 218 (“Spevak Decl.”) ¶ 6; Dkt. No. 220 (“Zhang Decl.”) ¶ 8.¹⁶
12 Plexxikon submits corroborating evidence that the inventors considered elements within the scope
13 of the claims to be particularly desirable. For instance, the March 2005 email states that “Chao’s
14 first suggestion at X is a Pyr”—a pyridine—which Dr. Metzker states is a monocyclic heteroaryl.
15 *See* Metzker Report ¶¶ 44-46. Although Dr. Metzker does not directly opine that the resulting
16 compound satisfies the claims, Novartis’ expert, Dr. Baran, does not dispute that a pyridine
17 satisfies the claimed Ar group. *See* Baran Reply Decl.¹⁷ Moreover, with respect to the linker L₁,
18 Dr. Metzker points out that the fourth bullet point of email states that the ketone linker “does not
19 need to stay,” which may suggest a direct bond. *See* Metzker Report ¶ 46.

20

21 ¹⁵ Novartis argues that Plexxikon’s “email” theory was not disclosed in discovery. The Court
22 disagrees. Plexxikon’s interrogatory responses disclosed the exact figures that it now relies on to
23 support conception. *See* Dkt. No. 393-37 at 12-14.

24 ¹⁶ The breadth of the purported conception of “X” may cut both ways. In *Jolley*, the court
25 suggested that an overgeneralized disclosure, such as “esters,” would not show conception of the
26 claimed ester groups with particularity, even though they would be encompassed within the
27 disclosure. *See* 308 F.3d at 1322. Thus, it is not enough that X encompasses the claimed groups:
28 the evidence must show a “preference” or “desirability” of the claimed groups compared to other
moieties that “interact with the hinge region of the kinase” (or that the class of such moieties is
sufficiently small, comparable to a “two ester” group). *See id.* at 1322-23, 1325.

17 ¹⁷ Novartis argues that the March 2005 email must be interpreted from the perspective of one of
ordinary skill in the art. The inventors in this case (as well as Dr. Baran) appear to have such skill.

With respect to the variables, Dr. Baran does not apparently dispute that the email shows elements that correspond to the limitations.¹⁸ For instance, with respect to R², the email shows a fluorine, which Dr. Baran concedes satisfies the claims, even if it does not show possession of other halogens or a hydrogen. Baran Reply Decl. ¶ 2 (sub-¶ 50). With respect to R³, Dr. Baran similarly does not dispute that the five “Z” groups satisfy the element, and opines only that they do not show possession of the trillions of other allowed moieties. *Id.* ¶ 2 (sub-¶ 51). Neither party addresses the R¹ or m variables. Accordingly, a reasonable jury could find that the March 2005 email shows conception of species that expressly meet most claim limitations and that show a “preference” for X groups falling within the scope of the claims.

Novartis separately argues that even if Plexxikon conceived the structure, it lacked an operative method for making the compounds where L₁ is a direct bond. *See Oka*, 849 F.3d at 583. Plexxikon proffers expert opinion, however, that methods for doing so were a matter of “routine knowledge,” which obviates the need for such evidence. *Id.*; Dkt. No. 399-5 (“Winkler Report”) ¶¶ 124-29, 201.¹⁹ Although Novartis suggests that these methods may not be sufficient for *all* claimed compounds, *see* Dkt. No. 393-4 (“Bridges Depo.”) at 99:11-101:10, it does not tie this argument to the March 2005 email—i.e., it does not show that the method was insufficient for the five species shown in the email. *See Oka*, 849 F.2d at 584 (considering this requirement on a species-by-species basis). This evidence therefore does not defeat Plexxikon’s showing.

Accordingly, the Court finds that Plexxikon meets its burden of production to show conception of a species by proffering the March 2005 email, and Novartis has not shown the evidence to be insufficient for this purpose.

//

¹⁸ Novartis relies heavily on a purported admission by Dr. Metzker that Plexxikon conceived the “scaffold” in 2005. Metzker Depo. at 192:15-23. The Court agrees with Plexxikon that this statement does not unambiguously suggest that other elements were not conceived.

¹⁹ Novartis’ cited authorities are inapposite. *Creative Compounds, LLC v. Starmark Laboratories*, 651 F.3d 1303, 1313 (Fed. Cir. 2011), involved a lack of expert support, and *Falana v. Kent State University*, 669 F.3d 1349, 1358 (Fed. Cir. 2012), expressly involved a “method that requires more than exercise of ordinary skill.”

1 **2. Priority for the Genus**

2 Novartis argues, however, that conception of a species cannot show conception of the
3 claimed genus in this case. Novartis cites Rule 131 reduction to practice cases stemming from
4 *Clarke*, 356 F.2d at 992, to argue that the evidence must also suggest “generic applicability.” *See*
5 *DaFano*, 392 F.2d at 284. In *Clarke*, the court found that reduction to practice of two species
6 having methyl and phenyl R groups was insufficient to establish priority for a genus where R
7 could be a large number of alternative elements. *See* 356 F.2d at 988-89, 992-93. Contrary to
8 Novartis’ suggestion, *Clarke* expressly recognizes that “in an appropriate case[,] a single species
9 could be sufficient” for antedation, even for broad claims. *Id.* at 992; *see id.* (“Claims do define
10 ‘the invention,’ but in a given case may be of varying scope while still defining the same
11 invention.”). However, in that case, the inventors themselves did not appear to consider any
12 elements besides methyl to be appropriate R groups having equivalent properties. *Id.* at 992-93.²⁰

13 Although *Clarke* is a reduction to practice and Rule 131 case, its basic principle accords
14 with modern conception law. As explained above, conception must be “complete” to establish
15 priority, and this requirement is defeated where “extensive research or experimentation” is
16 required to reduce the invention to practice. *Dawson*, 710 F.3d at 1352. Moreover, excessive
17 experimentation, particularly “experimental failures,” could “undermine[] the specificity of the
18 inventor’s idea” and thus show a lack of definiteness. *Burroughs*, 40 F.3d at 1229. The Court
19 therefore agrees that where more than “ordinary skill” would be required to determine the full
20 scope of the claims or the equivalence of alternative elements, conception is not established. *See*
21 *Dawson*, 710 F.3d at 1353 (no conception without definite idea of a concentration range).

22 Novartis has not, however, shown this to be the case here. According to Dr. Metzker, the
23 key feature of the claimed compounds that distinguishes it from other B-Raf inhibitors lies in the
24

25

²⁰ Specifically, the inventors did not consider the phenyl species to be part of the invention, which
26 left only the methyl species to show priority. *Clarke*, 356 F.2d at 993. Although methyl is
27 “structurally equivalent” to other alkyls, the evidence did not show the inventors considered other
28 alkyls to be equivalent. *Id.* at 992-93. The court noted, however, that reduction to practice of
“diverse” species could support priority by showing that the invention is “relatively independent
of the nature of the R substituent.” *Id.* at 993.

1 use of a monocyclic heteroaryl, in place of an azaindole, for the scaffold. *See Metzker Report ¶¶*
2 26-28. Plexxikon introduces evidence that the inventors conceived of this feature in March 2005,
3 including, for example, in a “weekly summary report” that proposed “to use [a] single ring to
4 replace the azaindole.” *Id.* ¶ 28. This evidence plausibly suggests the inventors had a “specific,
5 settled idea” and “particular solution” at the time. *Dawson*, 710 F.3d at 1352; *see also Amgen*,
6 927 F.2d at 1206 (requiring conception to define a compound through “whatever characteristics
7 sufficiently distinguish it”). As for the other variables, Novartis has not shown that more than
8 ordinary skill would be required to determine the equivalence of additional halogens and
9 hydrogens for R² or other lower alkyl or aryl groups for R³.

10 Accordingly, on this record, the Court cannot conclude that Plexxikon’s conception of a
11 species is insufficient to show conception of the claimed genus. *Cf. DaFano*, 392 F.2d at 284
12 (finding of single species sufficient for antedation where the inventors appreciated that “other
13 resin-soluble copper salts would behave similarly”).²¹ Novartis’ motion is therefore denied.

14 **IV. CONCLUSION**

15 For the foregoing reasons, the Court **DENIES** Novartis’ motion for summary judgment of
16 anticipation based on remaining disputes over the priority date of the Asserted Patents.

17
18 **IT IS SO ORDERED.**

19
20 Dated: 3/15/2021

21
22 
HAYWOOD S. GILLIAM, JR.
United States District Judge

23
24 _____
25 ²¹ Plexxikon relies on *Takeda Pharmaceutical Co. v. Two Pharmaceuticals, Inc.*, to argue that
conception of a species suffices. 87 F. Supp. 3d 1263 (N.D. Cal. 2015). There, Judge Koh cited
Jolley to deny summary judgment where the claims required “at least 10% more” of an element,
and the evidence showed conception of “at least 100% more.” *Id.* at 1276-77. As explained in
this Order, the Court agrees that conception of a species may establish priority for a genus in
appropriate circumstances. *See Jolley*, 308 F.3d at 1322 n.2. Here, the Court notes only that this
may not be the case where “extensive experimentation” belonging to the department of “creation,”
rather than “construction,” would be required to determine the full scope of the claims. *See*
Dawson, 710 F.3d at 1352.